PureTech Health (LON:PRTC) Trading Up 14.2% - Still a Buy?

Key Points

• PureTech Health plc's share price increased by 14.2%, with a trading volume surge of 1,053% compared to the average during a recent trading session.
• The company has a market capitalization of £293.65 million and a P/E ratio of 714.71, indicating very high valuation metrics.
• Recent insider activity saw Bharatt Chowrira purchase 167,739 shares at an average cost of GBX 1 per share, enhancing insider confidence.

PureTech Health plc (LON:PRTC - Get Free Report)'s stock price rose 14.2% during trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a 50 day moving average price of GBX 129.31 and a 200 day moving average price of GBX 129.65. The firm has a market cap of £302.59 million, a PE ratio of 736.47 and a beta of 1.02. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82.

Insider Activity at PureTech Health

In other news, insider Bharatt Chowrira purchased 167,739 shares of the firm's stock in a transaction dated Thursday, July 3rd. The shares were acquired at an average price of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by company insiders.

About PureTech Health

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.